Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$3.27NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22

Today's Change+0.15(4.81%)
Bid (Size)$3.15 (2)
Ask (Size)$3.28 (71)
Day Low / High$3.04 - 3.28
Volume483.5 K
  • Latest Stories
  • Commentary and Analysis
--Goldman Sachs Adjusts Price Target for Rhythm Pharmaceuticals to $9 From $10, Maintains Neutral Rating
1:25PM ET 4/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Finish Higher on Wednesday
4:10PM ET 4/06/2022 MT Newswires

Health care stocks continued to add their Wednesday advance, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) rising 1.9%...

Update: Rhythm Pharma Modifies Trials of Genetic Obesity Medicine; Shares Drop
3:01PM ET 4/06/2022 MT Newswires

(Updates with share price in the headline and last paragraph) Rhythm Pharmaceuticals (RYTM) said Wednesday it has modified phase 2 and 3 trials evaluating...

Sector Update: Health Care Stocks Climbing Wednesday Afternoon
2:07PM ET 4/06/2022 MT Newswires

Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 1.0%. ...

Rhythm Pharmaceuticals Modifies Trials of Genetic Obesity Medicine to Boost Chances of Success
9:32AM ET 4/06/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) said Wednesday it has modified phase 2 and 3 trials evaluating its setmelanotide medicine for rare genetic diseases of...

--Canaccord Genuity Adjusts Rhythm Pharmaceuticals Price Target to $36 From $45, Maintains Buy Rating
11:30AM ET 3/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Needham Lowers Rhythm Pharmaceuticals Price Target to $45 From $50, Maintains Buy Rating
12:50PM ET 2/25/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Rhythm Pharmaceuticals Says FDA Extends Review Period for Bardet-Biedl, Alstrom Syndrome Treatment Candidate
11:47AM ET 2/24/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) said Thursday the US Food and Drug Administration extended the review period for the supplemental new drug application for...

Rhythm Pharmaceuticals Shares Rise After Ladenburg Thalmann Upgrade
3:12PM ET 2/17/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) shares were up 16% in Thursday afternoon trading after Ladenburg Thalmann upgraded the biopharmaceutical company's stock to...

Ladenburg Thalmann Upgrades Rhythm Pharmaceuticals to Buy From Neutral; Price Target is $15
7:19AM ET 2/17/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $10 to $50, according to analysts polled by Capital IQ....